Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

"Spravato is now available as a stand-alone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days -- without the need for daily oral ...